teprenone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
mineralocorticoid receptor (MR, MCR, aldosterone receptor) antagonists 2596 6809-52-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • tetraprenylacetone
  • tetraprenyl acetone
  • teprenone
  • geranylgeranylacetone
  • selbex
; RN given refers to isomeric cpd without isomeric designation; mixture of (5E,9E,13E) & (5Z,9E,13E)-isomers
  • Molecular weight: 330.56
  • Formula: C23H38O
  • CLOGP: 7.92
  • LIPINSKI: None
  • HAC: 1
  • HDO: 0
  • TPSA: 17.07
  • ALOGS: -5.32
  • ROTB: 12

Drug dosage:

None

ADMET properties:

None

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hepatic function abnormal 75.11 25.08 35 2674 37107 63449206
Interstitial lung disease 66.19 25.08 38 2671 61870 63424443
Platelet count decreased 52.98 25.08 42 2667 116080 63370233
Renal impairment 46.94 25.08 35 2674 88320 63397993
Anaemia 40.76 25.08 56 2653 293374 63192939
Upper respiratory tract inflammation 40.02 25.08 11 2698 2512 63483801
White blood cell count decreased 38.68 25.08 38 2671 139066 63347247
Cerebral haemorrhage 35.87 25.08 20 2689 30709 63455604
Osteonecrosis of jaw 28.29 25.08 18 2691 35105 63451208
Cardiac failure 25.96 25.08 25 2684 89117 63397196
Aspartate aminotransferase increased 25.69 25.08 25 2684 90252 63396061

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Platelet count decreased 54.28 23.80 51 2160 119666 34835054
Anaemia 42.26 23.80 62 2149 233273 34721447
Hepatic function abnormal 41.69 23.80 29 2182 44334 34910386
Liver disorder 29.65 23.80 21 2190 32976 34921744
Decreased appetite 26.88 23.80 42 2169 166350 34788370
Neutrophil count decreased 25.45 23.80 23 2188 51081 34903639
C-reactive protein increased 24.33 23.80 23 2188 54075 34900645
White blood cell count decreased 24.27 23.80 30 2181 95415 34859305

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hepatic function abnormal 103.22 21.74 63 5272 73044 79666009
Platelet count decreased 97.56 21.74 90 5245 194574 79544479
Anaemia 70.87 21.74 115 5220 444900 79294153
Interstitial lung disease 68.16 21.74 58 5277 112542 79626511
White blood cell count decreased 57.85 21.74 67 5268 188221 79550832
Renal impairment 55.05 21.74 60 5275 157723 79581330
Upper respiratory tract inflammation 49.61 21.74 16 5319 4019 79735034
Liver disorder 45.22 21.74 38 5297 72379 79666674
Hyperuricaemia 42.26 21.74 19 5316 11780 79727273
Neutrophil count decreased 38.57 21.74 39 5296 93920 79645133
Cerebral haemorrhage 37.52 21.74 31 5304 57642 79681411
Enterocolitis 35.56 21.74 18 5317 14494 79724559
Drug eruption 33.67 21.74 26 5309 43909 79695144
Drug ineffective 32.48 21.74 16 5319 1080897 78658156
Fatigue 32.39 21.74 11 5324 929716 78809337
Pyrexia 32.24 21.74 109 5226 678600 79060453
Disseminated intravascular coagulation 31.44 21.74 23 5312 35819 79703234
Cerebral infarction 30.65 21.74 25 5310 45651 79693402
Erythema multiforme 29.54 21.74 17 5318 17634 79721419
Decreased appetite 28.00 21.74 67 5268 342351 79396702
Malignant neoplasm progression 26.95 21.74 39 5296 135951 79603102
Gamma-glutamyltransferase increased 26.75 21.74 25 5310 54655 79684398
Osteonecrosis of jaw 25.57 21.74 22 5313 43204 79695849
C-reactive protein increased 25.56 21.74 37 5298 128990 79610063
Gastric ulcer haemorrhage 24.49 21.74 12 5323 9015 79730038
Pneumonia 22.95 21.74 96 5239 660150 79078903
Alanine aminotransferase increased 21.75 21.74 39 5296 162531 79576522

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A02BX15 ALIMENTARY TRACT AND METABOLISM
DRUGS FOR ACID RELATED DISORDERS
DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)
MeSH PA D000897 Anti-Ulcer Agents
MeSH PA D000970 Antineoplastic Agents
MeSH PA D005765 Gastrointestinal Agents
CHEBI has role CHEBI:49201 anti-ulcer drugs
CHEBI has role CHEBI:62868 hepatoprotective agents
CHEBI has role CHEBI:63726 neuroprotective agents
CHEBI has role CHEBI:76595 nephroprotective agents
CHEBI has role CHEBI:77307 cardioprotective agents
CHEBI has role CHEBI:78606 heat shock protein 70 inducers

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
D01827 KEGG_DRUG
3796-63-2 SECONDARY_CAS_RN
C0061231 UMLSCUI
CHEBI:31649 CHEBI
CHEMBL79686 ChEMBL_ID
CHEMBL3989432 ChEMBL_ID
DB15955 DRUGBANK_ID
C031049 MESH_SUPPLEMENTAL_RECORD_UI
5282199 PUBCHEM_CID
5412 INN_ID
S8S8451A4O UNII
1362746 RXNORM

Pharmaceutical products:

None